Compare Regeneron Pharmaceuticals Inc (REGN) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Tyson Foods, Inc. — how do they compare? Regeneron Pharmaceuticals Inc trades at $745.44 (market cap $76.14B), while Tyson Foods, Inc. trades at $52.33 (market cap $18.41B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.1× Tyson Foods, Inc.'s market cap, and Tyson Foods, Inc. pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Tyson Foods, Inc. for 76 Days on average.
| REGN | TSN | |
|---|---|---|
Market Cap | $76.14B | $18.41B |
Volume | 500,239 | 3,757,599 |
Sector | Health | Consumer Staples |
52-Week High | $852.03 | $68.75 |
52-Week Low | $557.73 | $50.47 |
Typical Hold Time | 107 Days | 76 Days |
Enterprise Value | $70.85B | $25.68B |
Dividend Yield | 0.51% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
Tyson Foods (TSN) trades at $51.70, down 0.52% with mixed technical signals showing neutral overall but bearish moving averages. The company reported Q2 2026 EPS of $0.99, beating expectations, while Q4 2025 missed. Revenue grew to $54.44B in 2025 with thin 1.03% net margins. Analyst consensus is bullish with 53% buy ratings and $65.40 price target, though recent news highlights challenges in the beef segment and ongoing securities investigations.
The stock presents a value opportunity with low P/S (0.33) and reasonable EV/EBITDA (9.83), but faces significant execution risks from beef segment losses and margin pressure. Upside depends on successful business turnaround and resolution of legal concerns, while current price near 52-week lows offers potential for recovery if fundamentals improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
